Read More

MoonLake Immunotherapeutics’ Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week results, in which the primary endpoint was met with 29 percentage points delta 

MLTX

Read More

Aldeyra Therapeutics Says That The FDA Stated That Reproxalap For Signs And Symptoms Of Dry Eye Disease Does Not Appear To Have Data To Support The Clinical Relevance Of The Ocular Signs To Support The Dry Eye Indication – 8K

https://www.sec.gov/ix?doc=/Archives/edgar/data/1341235/000119312523256532/d760002d8k.htm In subsequent communications between Aldeyra and the FDA, Aldeyra has submitted responses to the FDA that Aldeyra believes to be

ALDX